Related Experiment Videos
Statins and liver toxicity: a meta-analysis.
Simon de Denus1, Sarah A Spinler, Kristin Miller
1Philadelphia College of Pharmacy, University of the Sciences in Philadelphia, PA 19103-4495, USA.
Pharmacotherapy
|May 28, 2004
Summary
Statins (3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors) generally show a low risk of liver function test abnormalities. Fluvastatin was the only statin associated with a significant increase in LFT abnormalities.
Area of Science:
- Cardiology
- Pharmacology
- Hepatology
Background:
- Hyperlipidemia management often involves statins.
- Liver function test (LFT) abnormalities are a potential concern with statin use.
- Assessing the safety profile of statins regarding LFTs is crucial for patient care.
Purpose of the Study:
- To evaluate the risk of liver function test abnormalities associated with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins).
- To determine the safety profile of various statins in hyperlipidemia treatment and cardiovascular disease prevention.
Main Methods:
- Meta-analysis of 13 randomized, placebo-controlled trials including 49,275 patients.
- Literature search of MEDLINE and Cochrane Controlled Trials Registry.
- Inclusion criteria: trials of at least 48 weeks duration with at least 400 patients (200 on statins).
Main Results:
- Overall, statin use showed a low proportion of LFT abnormalities (1.14% vs. 1.05% for placebo, OR 1.26, p=0.07).
- Fluvastatin was linked to a significant increase in LFT abnormalities compared to placebo (1.13% vs. 0.29%, OR 3.54, p=0.04), though based on limited data.
- Pravastatin, lovastatin, and simvastatin at low-to-moderate doses did not show a significant risk.
Conclusions:
- Pravastatin, lovastatin, and simvastatin at low-to-moderate doses appear safe regarding LFT abnormalities.
- Further research is needed to confirm the safety profile of other statins.
- The overall risk of LFT abnormalities with statins is low.